marketcaparena
Search

    GILD

    GILEAD SCIENCES, INC.

    Company overview

    Market capitalization
    $188.73B
    Employees
    17,000
    Latest publication
    2026-09-29
    About GILEAD SCIENCES, INC.

    Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue7,803,000,000USD6,960,000,000USD7,924,000,000USD7,769,000,000USD7,081,000,000USD6,667,000,000USD7,569,000,000USD7,545,000,000USD
    Cost Of Revenue1,579,000,000USD1,445,000,000USD1,624,000,000USD1,569,000,000USD1,501,000,000USD1,540,000,000USD1,581,000,000USD1,574,000,000USD
    Gross Profit6,224,000,000USD5,515,000,000USD6,300,000,000USD6,200,000,000USD5,580,000,000USD5,127,000,000USD5,988,000,000USD5,971,000,000USD
    Research Development1,764,000,000USD1,372,000,000USD1,584,000,000USD1,346,000,000USD1,491,000,000USD1,379,000,000USD1,641,000,000USD1,395,000,000USD
    Selling General Administrative1,921,000,000USD1,451,000,000USD652,000,000USD528,000,000USD501,000,000USD505,000,000USD992,000,000USD442,000,000USD
    Total Operating Expenses16,618,000,000USD2,929,000,000USD3,312,000,000USD2,873,000,000USD3,106,000,000USD2,890,000,000USD3,536,000,000USD5,083,000,000USD
    Operating Income-10,394,000,000USD2,586,000,000USD2,988,000,000USD3,327,000,000USD2,474,000,000USD2,237,000,000USD2,452,000,000USD888,000,000USD
    Total Other Income Expense Net140,000,000USD-6,000,000USD-910,000,000USD314,000,000USD-45,000,000USD-588,000,000USD-285,000,000USD68,000,000USD
    Interest Expense247,000,000USD240,000,000USD255,000,000USD256,000,000USD254,000,000USD260,000,000USD249,000,000USD238,000,000USD
    Income Before Tax-10,254,000,000USD2,580,000,000USD2,078,000,000USD3,641,000,000USD2,429,000,000USD1,649,000,000USD2,167,000,000USD956,000,000USD
    Income Tax Expense242,000,000USD559,000,000USD-105,000,000USD589,000,000USD468,000,000USD334,000,000USD385,000,000USD-297,000,000USD
    Net Income-10,496,000,000USD2,021,000,000USD2,183,000,000USD3,052,000,000USD1,960,000,000USD1,315,000,000USD1,783,000,000USD1,253,000,000USD
    Selling And Marketing Expenses——1,076,000,000USD829,000,000USD864,000,000USD753,000,000USD869,000,000USD968,000,000USD
    Interest Income——95,000,000USD88,000,000USD73,000,000USD94,000,000USD85,000,000USD52,000,000USD
    Net Interest Income——-160,000,000USD-168,000,000USD-181,000,000USD-166,000,000USD-164,000,000USD-186,000,000USD
    Tax Provision——-105,000,000USD589,000,000USD468,000,000USD334,000,000USD385,000,000USD-297,000,000USD
    Net Income From Continuing Ops——2,183,000,000USD3,052,000,000USD1,961,000,000USD1,315,000,000USD1,782,000,000USD1,253,000,000USD
    Ebit——2,333,000,000USD3,897,000,000USD2,683,000,000USD1,909,000,000USD2,416,000,000USD1,194,000,000USD
    Ebitda——3,020,000,000USD4,583,000,000USD3,374,000,000USD2,605,000,000USD3,109,000,000USD1,884,000,000USD
    Depreciation And Amortization——687,000,000USD686,000,000USD691,000,000USD696,000,000USD693,000,000USD690,000,000USD
    Reconciled Depreciation——687,000,000USD686,000,000USD691,000,000USD696,000,000USD693,000,000USD690,000,000USD
    Minority Interest——0USD0USD0USD0USD0USD0USD
    Unclassified Operating Expenses———170,000,000USD250,000,000USD253,000,000USD—2,278,000,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USDFY 20172017-12-31 · USDFY 20162016-12-31 · USD
    Total Revenue29,443,000,000USD28,754,000,000USD27,281,000,000USD27,305,000,000USD22,449,000,000USD22,127,000,000USD26,107,000,000USD30,390,000,000USD
    Cost Of Revenue6,234,000,000USD6,251,000,000USD5,657,000,000USD6,601,000,000USD4,675,000,000USD4,853,000,000USD4,371,000,000USD4,261,000,000USD
    Gross Profit23,209,000,000USD22,503,000,000USD21,624,000,000USD20,704,000,000USD17,774,000,000USD17,274,000,000USD21,736,000,000USD26,129,000,000USD
    Research Development5,799,000,000USD5,907,000,000USD4,977,000,000USD4,601,000,000USD4,055,000,000USD3,920,000,000USD3,734,000,000USD5,098,000,000USD
    Selling General Administrative5,774,000,000USD2,638,000,000USD4,895,000,000USD4,511,000,000USD3,597,000,000USD4,056,000,000USD3,878,000,000USD3,398,000,000USD
    Total Operating Expenses13,187,000,000USD20,841,000,000USD14,294,000,000USD10,786,000,000USD8,436,000,000USD7,976,000,000USD7,612,000,000USD8,496,000,000USD
    Operating Income10,022,000,000USD1,662,000,000USD7,330,000,000USD9,918,000,000USD4,287,000,000USD8,200,000,000USD14,124,000,000USD17,633,000,000USD
    Total Other Income Expense Net-226,000,000USD-972,000,000USD-1,516,000,000USD-1,640,000,000USD873,000,000USD-401,000,000USD-595,000,000USD-536,000,000USD
    Interest Expense1,024,000,000USD977,000,000USD935,000,000USD1,001,000,000USD995,000,000USD1,077,000,000USD1,118,000,000USD964,000,000USD
    Income Before Tax9,796,000,000USD690,000,000USD5,814,000,000USD8,278,000,000USD5,160,000,000USD7,799,000,000USD13,529,000,000USD17,097,000,000USD
    Income Tax Expense1,286,000,000USD211,000,000USD1,248,000,000USD2,077,000,000USD-204,000,000USD2,339,000,000USD8,885,000,000USD3,609,000,000USD
    Net Income8,510,000,000USD480,000,000USD4,592,000,000USD6,225,000,000USD5,386,000,000USD5,455,000,000USD4,628,000,000USD13,501,000,000USD
    Minority Interest0USD0USD26,000,000USD24,000,000USD-22,000,000USD5,000,000USD16,000,000USD-13,000,000USD
    Selling And Marketing Expenses—3,453,000,000USD778,000,000USD735,000,000USD784,000,000USD———
    Unclassified Operating Expenses—8,843,000,000USD3,644,000,000USD939,000,000USD————
    Interest Income—281,000,000USD106,000,000USD—227,000,000USD964,000,000USD1,190,000,000USD790,000,000USD
    Net Interest Income—-696,000,000USD-935,000,000USD-1,001,000,000USD-995,000,000USD-1,077,000,000USD-1,118,000,000USD-964,000,000USD
    Tax Provision—211,000,000USD1,248,000,000USD2,077,000,000USD-204,000,000USD2,339,000,000USD8,885,000,000USD3,609,000,000USD
    Net Income From Continuing Ops—479,000,000USD4,566,000,000USD6,201,000,000USD5,364,000,000USD5,460,000,000USD4,644,000,000USD13,488,000,000USD
    Ebit—1,667,000,000USD6,749,000,000USD9,279,000,000USD6,155,000,000USD8,876,000,000USD14,647,000,000USD18,061,000,000USD
    Ebitda—4,434,000,000USD8,852,000,000USD11,329,000,000USD7,559,000,000USD10,305,000,000USD15,933,000,000USD19,219,000,000USD
    Depreciation And Amortization—2,767,000,000USD2,103,000,000USD2,050,000,000USD1,404,000,000USD1,429,000,000USD1,286,000,000USD1,158,000,000USD
    Reconciled Depreciation—2,767,000,000USD2,103,000,000USD2,050,000,000USD1,404,000,000USD1,429,000,000USD1,286,000,000USD—
    Non Operating Income Net Other——-581,000,000USD-639,000,000USD1,868,000,000USD676,000,000USD523,000,000USD428,000,000USD
    Net Income Applicable To Common Shares——4,592,000,000USD6,225,000,000USD5,386,000,000USD5,455,000,000USD4,628,000,000USD13,501,000,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets49,362,000,000USD56,278,000,000USD59,023,000,000USD58,533,000,000USD55,721,000,000USD56,434,000,000USD58,995,000,000USD54,525,000,000USD
    Short Term Investments0USD15,000,000USD68,000,000USD19,000,000USD69,000,000USD785,000,000USD1,577,000,000USD1,660,000,000USD
    Long Term Investments0USD983,000,000USD2,974,000,000USD2,005,000,000USD1,913,000,000USD—0USD0USD
    Total Current Assets13,945,000,000USD18,641,000,000USD18,342,000,000USD17,874,000,000USD14,718,000,000USD16,901,000,000USD19,173,000,000USD14,779,000,000USD
    Other Current Assets3,759,000,000USD4,342,000,000USD4,024,000,000USD3,645,000,000USD2,899,000,000USD2,828,000,000USD1,475,000,000USD1,626,000,000USD
    Other Non Current Assets4,751,000,000USD4,554,000,000USD4,845,000,000USD—————
    Total Liabilities37,618,000,000USD32,847,000,000USD36,405,000,000USD—————
    Total Current Liabilities11,020,000,000USD9,476,000,000USD11,813,000,000USD12,297,000,000USD11,189,000,000USD12,343,000,000USD12,004,000,000USD11,724,000,000USD
    Other Current Liabilities3,699,000,000USD3,399,000,000USD3,953,000,000USD—————
    Other Non Current Liabilities1,490,000,000USD1,200,000,000USD1,165,000,000USD—————
    Total Stockholder Equity11,829,000,000USD23,515,000,000USD22,703,000,000USD21,540,000,000USD19,675,000,000USD19,162,000,000USD19,330,000,000USD18,474,000,000USD
    Total Equity Including Noncontrolling Interest11,744,000,000USD23,431,000,000USD22,618,000,000USD—————
    Short Long Term Debt2,414,000,000USD1,313,000,000USD2,807,000,000USD2,806,000,000USD2,806,000,000USD2,806,000,000USD1,815,000,000USD1,812,000,000USD
    Long Term Debt23,832,000,000USD20,861,000,000USD22,129,000,000USD22,135,000,000USD22,140,000,000USD22,146,000,000USD24,896,000,000USD21,437,000,000USD
    Net Receivables5,055,000,000USD4,741,000,000USD4,913,000,000USD5,095,000,000USD4,781,000,000USD4,388,000,000USD4,420,000,000USD4,587,000,000USD
    Inventory1,953,000,000USD1,914,000,000USD1,774,000,000USD1,785,000,000USD1,825,000,000USD1,759,000,000USD1,710,000,000USD1,869,000,000USD
    Property Plant Equipment Net5,833,000,000USD5,638,000,000USD6,138,000,000USD5,500,000,000USD5,459,000,000USD5,421,000,000USD5,414,000,000USD5,391,000,000USD
    Goodwill8,314,000,000USD8,314,000,000USD8,314,000,000USD—————
    Intangible Assets14,032,000,000USD16,382,000,000USD16,978,000,000USD17,969,000,000USD18,567,000,000USD19,354,000,000USD19,948,000,000USD20,545,000,000USD
    Accounts Payable674,000,000USD645,000,000USD715,000,000USD808,000,000USD582,000,000USD737,000,000USD833,000,000USD903,000,000USD
    Short Term Debt2,414,000,000USD1,313,000,000USD2,807,000,000USD2,806,000,000USD2,806,000,000USD2,806,000,000USD1,928,000,000USD1,812,000,000USD
    Common Stock1,000,000USD1,000,000USD1,000,000USD1,000,000USD1,000,000USD1,000,000USD1,000,000USD1,000,000USD
    Retained Earnings2,200,000,000USD14,131,000,000USD13,730,000,000USD12,825,000,000USD11,325,000,000USD10,931,000,000USD11,497,000,000USD11,073,000,000USD
    Accumulated Other Comprehensive Income95,000,000USD78,000,000USD39,000,000USD36,000,000USD-18,000,000USD92,000,000USD132,000,000USD73,000,000USD
    Cash And Equivalents3,179,000,000USD7,628,000,000USD——————
    Total Liab———37,077,000,000USD36,130,000,000USD37,356,000,000USD39,749,000,000USD36,135,000,000USD
    Other Current Liab———8,683,000,000USD7,801,000,000USD8,800,000,000USD7,597,000,000USD7,473,000,000USD
    Capital Stock———1,000,000USD1,000,000USD1,000,000USD1,000,000USD1,000,000USD
    Good Will———8,314,000,000USD8,314,000,000USD8,314,000,000USD8,314,000,000USD8,314,000,000USD
    Other Assets———7,913,000,000USD-2,000,000USD1,000,000USD-1,000,000USD2,000,000USD
    Cash———7,330,000,000USD5,144,000,000USD7,926,000,000USD9,991,000,000USD5,037,000,000USD
    Cash And Short Term Investments———7,349,000,000USD5,213,000,000USD7,926,000,000USD11,568,000,000USD6,697,000,000USD
    Net Debt———17,611,000,000USD19,802,000,000USD17,026,000,000USD17,331,000,000USD18,212,000,000USD
    Short Long Term Debt Total———24,941,000,000USD24,946,000,000USD24,952,000,000USD27,322,000,000USD23,249,000,000USD
    Property Plant Equipment Gross———8,193,000,000USD8,080,000,000USD7,963,000,000USD7,884,000,000USD—
    Common Stock Shares Outstanding———1,254,000,000shares1,255,000,000shares1,259,000,000shares1,259,000,000shares1,254,000,000shares
    Non Current Assets Total———40,659,000,000USD41,005,000,000USD39,532,000,000USD39,823,000,000USD39,744,000,000USD
    Non Current Liabilities Total———24,780,000,000USD24,941,000,000USD25,013,000,000USD27,745,000,000USD24,411,000,000USD
    Non Current Liabilities Other———1,182,000,000USD1,290,000,000USD1,339,000,000USD1,295,000,000USD1,398,000,000USD
    Non Currrent Assets Other———4,873,000,000USD4,031,000,000USD3,187,000,000USD3,769,000,000USD4,764,000,000USD
    Net Working Capital———5,577,000,000USD3,529,000,000USD4,558,000,000USD7,169,000,000USD3,055,000,000USD
    Unclassified Non Current Assets———-5,915,000,000USD2,721,000,000USD3,255,000,000USD2,378,000,000USD728,000,000USD
    Unclassified Current Liabilities———-2,806,000,000USD-2,806,000,000USD-2,806,000,000USD-169,000,000USD-276,000,000USD
    Unclassified Non Current Liabilities———1,463,000,000USD1,511,000,000USD1,528,000,000USD1,554,000,000USD1,576,000,000USD
    Unclassified Equity———8,677,000,000USD8,366,000,000USD8,137,000,000USD7,699,000,000USD7,326,000,000USD
    Unclassified Current Assets—————-785,000,000USD——
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets59,023,000,000USD58,995,000,000USD62,125,000,000USD63,171,000,000USD67,952,000,000USD68,407,000,000USD61,627,000,000USD63,675,000,000USD
    Short Term Investments68,000,000USD1,577,000,000USD1,179,000,000USD973,000,000USD1,182,000,000USD1,411,000,000USD12,721,000,000USD12,149,000,000USD
    Long Term Investments2,974,000,000USD0USD1,163,000,000USD1,245,000,000USD1,309,000,000USD502,000,000USD1,488,000,000USD1,423,000,000USD
    Total Current Assets18,342,000,000USD19,173,000,000USD16,085,000,000USD14,443,000,000USD14,772,000,000USD15,996,000,000USD30,296,000,000USD35,836,000,000USD
    Other Current Assets4,024,000,000USD1,475,000,000USD2,374,000,000USD1,774,000,000USD2,141,000,000USD2,013,000,000USD1,440,000,000USD1,606,000,000USD
    Other Non Current Assets4,845,000,000USD———————
    Total Liabilities36,405,000,000USD———————
    Total Current Liabilities11,813,000,000USD12,004,000,000USD11,280,000,000USD11,238,000,000USD11,610,000,000USD11,397,000,000USD9,759,000,000USD10,605,000,000USD
    Other Current Liabilities3,953,000,000USD———————
    Other Non Current Liabilities1,165,000,000USD———————
    Total Stockholder Equity22,703,000,000USD19,330,000,000USD22,833,000,000USD21,240,000,000USD21,069,000,000USD18,202,000,000USD22,525,000,000USD21,387,000,000USD
    Total Equity Including Noncontrolling Interest22,618,000,000USD———————
    Short Long Term Debt2,807,000,000USD1,815,000,000USD1,798,000,000USD2,273,000,000USD1,516,000,000USD2,757,000,000USD2,499,000,000USD2,748,000,000USD
    Long Term Debt22,129,000,000USD24,896,000,000USD23,189,000,000USD22,957,000,000USD25,179,000,000USD28,645,000,000USD22,094,000,000USD24,574,000,000USD
    Net Receivables4,913,000,000USD4,420,000,000USD4,660,000,000USD4,777,000,000USD4,493,000,000USD4,892,000,000USD3,582,000,000USD3,327,000,000USD
    Inventory1,774,000,000USD1,710,000,000USD1,787,000,000USD1,507,000,000USD1,618,000,000USD1,683,000,000USD922,000,000USD814,000,000USD
    Property Plant Equipment Net6,138,000,000USD5,414,000,000USD5,317,000,000USD5,475,000,000USD5,121,000,000USD4,967,000,000USD4,502,000,000USD4,006,000,000USD
    Goodwill8,314,000,000USD———————
    Intangible Assets16,978,000,000USD19,948,000,000USD26,454,000,000USD28,893,000,000USD33,455,000,000USD33,126,000,000USD13,786,000,000USD15,738,000,000USD
    Accounts Payable715,000,000USD833,000,000USD550,000,000USD905,000,000USD705,000,000USD844,000,000USD713,000,000USD790,000,000USD
    Short Term Debt2,807,000,000USD1,815,000,000USD1,798,000,000USD2,273,000,000USD1,516,000,000USD2,757,000,000USD2,499,000,000USD2,748,000,000USD
    Common Stock1,000,000USD1,000,000USD1,000,000USD1,000,000USD1,000,000USD1,000,000USD1,000,000USD1,000,000USD
    Retained Earnings13,730,000,000USD11,497,000,000USD16,304,000,000USD15,687,000,000USD16,324,000,000USD14,381,000,000USD19,388,000,000USD19,024,000,000USD
    Accumulated Other Comprehensive Income39,000,000USD132,000,000USD28,000,000USD2,000,000USD83,000,000USD-60,000,000USD85,000,000USD80,000,000USD
    Total Liab—39,749,000,000USD39,376,000,000USD41,962,000,000USD46,888,000,000USD50,186,000,000USD38,977,000,000USD42,141,000,000USD
    Other Current Liab—8,526,000,000USD7,724,000,000USD7,101,000,000USD8,850,000,000USD7,198,000,000USD6,260,000,000USD6,877,000,000USD
    Capital Stock—1,000,000USD1,000,000USD1,000,000USD1,000,000USD1,000,000USD1,000,000USD1,000,000USD
    Good Will—8,314,000,000USD8,314,000,000USD8,314,000,000USD8,332,000,000USD8,108,000,000USD4,117,000,000USD4,117,000,000USD
    Other Assets—-1,000,000USD—1,000,000USD5,988,000,000USD4,799,000,000USD3,119,000,000USD2,413,000,000USD
    Cash—9,991,000,000USD6,085,000,000USD5,412,000,000USD5,338,000,000USD5,997,000,000USD11,631,000,000USD17,940,000,000USD
    Cash And Short Term Investments—11,568,000,000USD7,264,000,000USD6,385,000,000USD6,520,000,000USD7,408,000,000USD24,352,000,000USD30,089,000,000USD
    Net Debt—16,720,000,000USD18,902,000,000USD19,818,000,000USD21,357,000,000USD25,405,000,000USD12,962,000,000USD9,382,000,000USD
    Short Long Term Debt Total—26,711,000,000USD24,987,000,000USD25,230,000,000USD26,695,000,000USD31,402,000,000USD24,593,000,000USD27,322,000,000USD
    Property Plant Equipment Gross—7,884,000,000USD7,766,000,000USD7,661,000,000USD7,014,000,000USD4,967,000,000USD4,502,000,000USD4,006,000,000USD
    Common Stock Shares Outstanding—1,255,000,000shares1,258,000,000shares1,262,000,000shares1,262,000,000shares1,263,000,000shares1,277,000,000shares1,308,000,000shares
    Non Current Assets Total—39,823,000,000USD46,040,000,000USD48,727,000,000USD53,180,000,000USD52,411,000,000USD31,331,000,000USD27,839,000,000USD
    Non Current Liabilities Total—27,745,000,000USD28,096,000,000USD30,724,000,000USD35,278,000,000USD38,789,000,000USD29,218,000,000USD31,536,000,000USD
    Non Current Liabilities Other—1,295,000,000USD1,280,000,000USD5,095,000,000USD5,743,000,000USD10,144,000,000USD7,124,000,000USD6,962,000,000USD
    Non Currrent Assets Other—3,769,000,000USD4,792,000,000USD4,800,000,000USD4,963,000,000USD5,708,000,000USD7,438,000,000USD2,555,000,000USD
    Net Working Capital—7,169,000,000USD4,805,000,000USD3,990,000,000USD3,446,000,000USD4,599,000,000USD20,537,000,000USD25,231,000,000USD
    Unclassified Non Current Assets—2,378,000,000USD——-5,988,000,000USD-4,799,000,000USD-3,119,000,000USD-2,413,000,000USD
    Unclassified Current Liabilities—-985,000,000USD-590,000,000USD-1,314,000,000USD-977,000,000USD-2,159,000,000USD-2,212,000,000USD-2,558,000,000USD
    Unclassified Non Current Liabilities—1,554,000,000USD3,627,000,000USD-7,302,000,000USD-35,278,000,000USD-9,536,000,000USD-6,498,000,000USD-6,962,000,000USD
    Unclassified Equity—7,699,000,000USD——————
    Current Deferred Revenue——-2,348,000,000USD—————
    Additional Paid In Capital——6,500,000,000USD5,550,000,000USD4,661,000,000USD3,880,000,000USD3,051,000,000USD2,282,000,000USD
    Treasury Stock——0USD0USD0USD0USD0USD0USD
    Deferred Long Term Liab———2,673,000,000USD4,356,000,000USD———
    Other Liab———7,301,000,000USD35,278,000,000USD9,536,000,000USD6,498,000,000USD6,962,000,000USD
    Net Tangible Assets———-15,968,000,000USD-20,723,000,000USD-23,032,000,000USD4,622,000,000USD1,532,000,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation191,000,000USD
    Stock Based Compensation449,000,000USD
    Deferred Income Tax-408,000,000USD
    Other Non Cash Items-423,000,000USD
    Change To Account Receivables-199,000,000USD
    Change To Inventory-197,000,000USD
    Change To Liabilities-413,000,000USD
    Change In Working Capital-453,000,000USD
    Operating Cash Flow6,117,000,000USD
    Capital Expenditures-257,000,000USD
    Net Investments2,995,000,000USD
    Other Investing Activities-11,321,000,000USD
    Unclassified Investing Cash Flow6,000,000USD
    Investing Cash Flow-8,577,000,000USD
    Net Debt Issuance-2,783,000,000USD
    Net Common Stock Issuance-774,000,000USD
    Common Dividends Paid-2,069,000,000USD
    Other Financing Activities-529,000,000USD
    Unclassified Financing Cash Flow4,260,000,000USD
    Financing Cash Flow-1,895,000,000USD
    Effect Of Forex Changes On Cash-30,000,000USD
    Change In Cash-4,385,000,000USD
    End Cash Flow3,179,000,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Depreciation93,000,000USD687,000,000USD686,000,000USD691,000,000USD696,000,000USD693,000,000USD690,000,000USD694,000,000USD
    Stock Based Compensation218,000,000USD230,000,000USD230,000,000USD225,000,000USD209,000,000USD222,000,000USD216,000,000USD210,000,000USD
    Deferred Income Tax179,000,000USD———————
    Other Non Cash Items-183,000,000USD953,000,000USD-222,000,000USD143,000,000USD769,000,000USD173,000,000USD2,084,000,000USD519,000,000USD
    Change To Account Receivables134,000,000USD179,000,000USD-333,000,000USD-292,000,000USD79,000,000USD72,000,000USD162,000,000USD-29,000,000USD
    Change To Inventory-52,000,000USD-123,000,000USD-515,000,000USD-175,000,000USD-223,000,000USD-226,000,000USD-85,000,000USD-70,000,000USD
    Change To Liabilities-769,000,000USD———————
    Change In Working Capital20,000,000USD-604,000,000USD-297,000,000USD-2,014,000,000USD-1,033,000,000USD483,000,000USD642,000,000USD-1,546,000,000USD
    Operating Cash Flow2,544,000,000USD———————
    Capital Expenditures-117,000,000USD-205,000,000USD-147,000,000USD-107,000,000USD-104,000,000USD-147,000,000USD-141,000,000USD-130,000,000USD
    Net Investments2,012,000,000USD———————
    Other Investing Activities-92,000,000USD———————
    Unclassified Investing Cash Flow-33,000,000USD-609,000,000USD144,000,000USD97,000,000USD126,000,000USD111,000,000USD131,000,000USD121,000,000USD
    Investing Cash Flow1,770,000,000USD———————
    Net Debt Issuance-2,766,000,000USD———————
    Net Common Stock Issuance-419,000,000USD———————
    Common Dividends Paid-1,040,000,000USD———————
    Other Financing Activities-179,000,000USD———————
    Unclassified Financing Cash Flow165,000,000USD32,000,000USD97,000,000USD27,000,000USD252,000,000USD173,000,000USD98,000,000USD-1,846,000,000USD
    Financing Cash Flow-4,239,000,000USD———————
    Effect Of Forex Changes On Cash-11,000,000USD———————
    Change In Cash65,000,000USD234,000,000USD2,186,000,000USD-2,782,000,000USD-2,065,000,000USD4,954,000,000USD2,265,000,000USD-1,946,000,000USD
    End Cash Flow7,628,000,000USD———————
    Net Income—2,183,000,000USD3,052,000,000USD1,960,000,000USD1,315,000,000USD1,783,000,000USD1,253,000,000USD1,614,000,000USD
    Total Cash From Operating Activities—3,327,000,000USD4,108,000,000USD827,000,000USD1,757,000,000USD2,975,000,000USD4,309,000,000USD1,325,000,000USD
    Free Cash Flow—3,121,000,000USD3,961,000,000USD720,000,000USD1,653,000,000USD2,828,000,000USD4,168,000,000USD1,195,000,000USD
    Investments—-1,033,000,000USD-427,000,000USD-2,116,000,000USD-415,000,000USD-225,000,000USD-710,000,000USD-307,000,000USD
    Total Cashflows From Investing Activities—-1,835,000,000USD-427,000,000USD-2,116,000,000USD-415,000,000USD-225,000,000USD-710,000,000USD-307,000,000USD
    Net Borrowings—-8,000,000USD-9,000,000USD-9,000,000USD-1,762,000,000USD3,457,000,000USD-112,000,000USD—
    Total Cash From Financing Activities—-1,263,000,000USD-1,489,000,000USD-1,567,000,000USD-3,426,000,000USD2,260,000,000USD-1,379,000,000USD-2,953,000,000USD
    Dividends Paid—-994,000,000USD-1,005,000,000USD-994,000,000USD-1,010,000,000USD-973,000,000USD-983,000,000USD-972,000,000USD
    Sale Purchase Of Stock—-230,000,000USD-435,000,000USD-527,000,000USD-730,000,000USD-350,000,000USD-300,000,000USD-100,000,000USD
    Issuance Of Capital Stock—32,000,000USD97,000,000USD27,000,000USD252,000,000USD173,000,000USD98,000,000USD5,000,000USD
    Begin Period Cash Flow—7,330,000,000USD5,144,000,000USD7,926,000,000USD9,991,000,000USD5,037,000,000USD2,772,000,000USD4,718,000,000USD
    End Period Cash Flow—7,564,000,000USD7,330,000,000USD5,144,000,000USD7,926,000,000USD9,991,000,000USD5,037,000,000USD2,772,000,000USD
    Other Cashflows From Investing Activities—12,000,000USD3,000,000USD10,000,000USD-22,000,000USD36,000,000USD10,000,000USD9,000,000USD
    Other Cashflows From Financing Activities—-63,000,000USD-137,000,000USD-64,000,000USD-176,000,000USD-47,000,000USD-82,000,000USD-35,000,000USD
    Unclassified Operating Cash Flow—-122,000,000USD659,000,000USD-178,000,000USD-199,000,000USD-379,000,000USD-576,000,000USD-166,000,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Depreciation2,770,000,000USD2,767,000,000USD2,693,000,000USD2,103,000,000USD2,050,000,000USD1,480,000,000USD1,404,000,000USD1,429,000,000USD
    Stock Based Compensation894,000,000USD835,000,000USD766,000,000USD637,000,000USD635,000,000USD643,000,000USD636,000,000USD845,000,000USD
    Deferred Income Tax160,000,000USD———————
    Other Non Cash Items-480,000,000USD9,470,000,000USD2,147,000,000USD5,081,000,000USD2,125,000,000USD7,808,000,000USD4,636,000,000USD1,316,000,000USD
    Change To Account Receivables-367,000,000USD139,000,000USD157,000,000USD-406,000,000USD313,000,000USD-1,171,000,000USD-218,000,000USD480,000,000USD
    Change To Inventory-1,036,000,000USD-426,000,000USD-842,000,000USD-310,000,000USD11,000,000USD-195,000,000USD-95,000,000USD-310,000,000USD
    Change To Liabilities-126,000,000USD——-1,117,000,000USD207,000,000USD-58,000,000USD-178,000,000USD-2,012,000,000USD
    Change In Working Capital-1,846,000,000USD-880,000,000USD-2,303,000,000USD-1,763,000,000USD489,000,000USD-1,638,000,000USD-798,000,000USD-939,000,000USD
    Operating Cash Flow10,019,000,000USD———————
    Capital Expenditures-563,000,000USD-523,000,000USD-585,000,000USD-728,000,000USD-579,000,000USD-650,000,000USD-825,000,000USD-924,000,000USD
    Net Investments-3,163,000,000USD———————
    Other Investing Activities-1,072,000,000USD———————
    Unclassified Investing Cash Flow5,000,000USD465,000,000USD233,000,000USD2,526,000,000USD3,710,000,000USD——190,000,000USD
    Investing Cash Flow-4,793,000,000USD———————
    Net Debt Issuance-1,788,000,000USD———————
    Net Common Stock Issuance-1,922,000,000USD———————
    Common Dividends Paid-4,003,000,000USD———————
    Other Financing Activities-440,000,000USD———————
    Unclassified Financing Cash Flow408,000,000USD422,000,000USD232,000,000USD309,000,000USD169,000,000USD-7,928,000,000USD209,000,000USD289,000,000USD
    Financing Cash Flow-7,745,000,000USD———————
    Effect Of Forex Changes On Cash92,000,000USD———————
    Change In Cash-2,428,000,000USD3,906,000,000USD673,000,000USD74,000,000USD-659,000,000USD-5,634,000,000USD-6,309,000,000USD10,352,000,000USD
    End Cash Flow7,564,000,000USD———————
    Net Income—480,000,000USD5,665,000,000USD4,566,000,000USD6,201,000,000USD89,000,000USD5,364,000,000USD5,460,000,000USD
    Total Cash From Operating Activities—10,828,000,000USD8,006,000,000USD9,072,000,000USD11,384,000,000USD8,168,000,000USD9,144,000,000USD8,400,000,000USD
    Free Cash Flow—10,305,000,000USD7,421,000,000USD8,344,000,000USD10,805,000,000USD7,518,000,000USD8,319,000,000USD7,476,000,000USD
    Investments—-3,449,000,000USD-1,913,000,000USD-2,466,000,000USD-3,131,000,000USD11,948,000,000USD-2,307,000,000USD15,279,000,000USD
    Total Cashflows From Investing Activities—-3,449,000,000USD-2,265,000,000USD-2,466,000,000USD-3,131,000,000USD-14,615,000,000USD-7,817,000,000USD14,355,000,000USD
    Net Borrowings—1,494,000,000USD-270,000,000USD-1,500,000,000USD-4,750,000,000USD5,684,000,000USD-2,750,000,000USD-6,250,000,000USD
    Total Cash From Financing Activities—-3,433,000,000USD-5,125,000,000USD-6,469,000,000USD-8,877,000,000USD770,000,000USD-7,634,000,000USD-12,318,000,000USD
    Dividends Paid—-3,918,000,000USD-3,809,000,000USD-3,709,000,000USD-3,605,000,000USD-3,449,000,000USD-3,222,000,000USD-2,971,000,000USD
    Sale Purchase Of Stock—-1,150,000,000USD-1,000,000,000USD-1,396,000,000USD-546,000,000USD-1,583,000,000USD-1,749,000,000USD-2,900,000,000USD
    Issuance Of Capital Stock—422,000,000USD382,000,000USD309,000,000USD169,000,000USD256,000,000USD209,000,000USD289,000,000USD
    Begin Period Cash Flow—6,085,000,000USD5,412,000,000USD5,338,000,000USD5,997,000,000USD11,631,000,000USD17,940,000,000USD7,588,000,000USD
    End Period Cash Flow—9,991,000,000USD6,085,000,000USD5,412,000,000USD5,338,000,000USD5,997,000,000USD11,631,000,000USD17,940,000,000USD
    Other Cashflows From Investing Activities—58,000,000USD—-1,798,000,000USD-3,131,000,000USD-25,913,000,000USD-4,685,000,000USD-190,000,000USD
    Other Cashflows From Financing Activities—-281,000,000USD-278,000,000USD-173,000,000USD-145,000,000USD8,046,000,000USD-122,000,000USD-486,000,000USD
    Unclassified Operating Cash Flow—-1,844,000,000USD-962,000,000USD-1,552,000,000USD-116,000,000USD-214,000,000USD-2,098,000,000USD289,000,000USD
    Cash And Cash Equivalents Changes———137,000,000USD-624,000,000USD-5,677,000,000USD-6,307,000,000USD10,352,000,000USD
    Exchange Rate Changes———————-85,000,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30GeographyEurope1,324,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30GeographyRest of World876,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30GeographyUnited States5,603,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31GeographyEurope1,144,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31GeographyRest of World889,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31GeographyUnited States4,926,000,000USDDisclosure
    Q4 2025Quarterly · 2025-12-31GeographyEurope1,236,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31GeographyRest of World813,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31GeographyUnited States5,876,000,000USDLegacy provider
    FY 2025Yearly · 2025-12-31GeographyEurope5,064,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31GeographyRest of World3,503,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31GeographyUnited States20,876,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30GeographyEurope1,555,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30GeographyRest of World933,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30GeographyUnited States5,281,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30GeographyEurope1,189,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30GeographyRest of World842,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30GeographyUnited States5,051,000,000USDDisclosure
    Q4 2024Quarterly · 2024-12-31GeographyEurope1,175,000,000USDDisclosure
    Q4 2024Quarterly · 2024-12-31GeographyRest of World827,000,000USDDisclosure
    Q4 2024Quarterly · 2024-12-31GeographyUnited States5,567,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31GeographyEurope4,634,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31GeographyRest of World3,529,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31GeographyUnited States20,591,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30GeographyEurope1,167,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30GeographyRest of World929,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30GeographyUnited States5,450,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30GeographyEurope1,133,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30GeographyRest of World879,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30GeographyUnited States4,941,000,000USDDisclosure
    FY 2023Yearly · 2023-12-31GeographyEurope4,310,000,000USDDisclosure
    FY 2023Yearly · 2023-12-31GeographyRest of World3,368,000,000USDDisclosure
    FY 2023Yearly · 2023-12-31GeographyUnited States19,438,000,000USDDisclosure
    FY 2022Yearly · 2022-12-31GeographyEurope4,469,000,000USDDisclosure
    FY 2022Yearly · 2022-12-31GeographyRest of World3,928,000,000USDDisclosure
    FY 2022Yearly · 2022-12-31GeographyUnited States18,884,000,000USDDisclosure
    FY 2021Yearly · 2021-12-31GeographyEurope4,874,000,000USD0000882095-24-000007
    FY 2021Yearly · 2021-12-31GeographyOther International3,164,000,000USD0000882095-24-000007
    FY 2021Yearly · 2021-12-31GeographyUnited States19,267,000,000USD0000882095-24-000007
    FY 2020Yearly · 2020-12-31GeographyEurope4,135,000,000USD0000882095-23-000007
    FY 2020Yearly · 2020-12-31GeographyOther International2,337,000,000USD0000882095-23-000007
    FY 2020Yearly · 2020-12-31GeographyUnited States18,217,000,000USD0000882095-23-000007
    Q3 2020Quarterly · 2020-09-30ProductProduct6,493,000,000USD0000882095-20-000027
    Q3 2020Quarterly · 2020-09-30ProductRoyalty Contract And Other84,000,000USD0000882095-20-000027
    Q2 2020Quarterly · 2020-06-30ProductProduct5,067,000,000USD0000882095-20-000019
    Q2 2020Quarterly · 2020-06-30ProductRoyalty Contract And Other76,000,000USD0000882095-20-000019
    Q1 2020Quarterly · 2020-03-31ProductProduct5,467,000,000USD0000882095-20-000013
    Q1 2020Quarterly · 2020-03-31ProductRoyalty Contract And Other81,000,000USD0000882095-20-000013
    FY 2019Yearly · 2019-12-31GeographyEurope3,811,000,000USD0000882095-22-000007
    FY 2019Yearly · 2019-12-31GeographyOther International1,993,000,000USD0000882095-22-000007
    FY 2019Yearly · 2019-12-31GeographyUnited States16,645,000,000USD0000882095-22-000007
    Q4 2019Quarterly · 2019-12-31ProductHCVProducts Ledipasvir Sofosbuvir101,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductHCVProducts Sofosbuvir Velpatasvir465,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductHCVProducts Vosevi56,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductHIVProducts Atripla128,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductHIVProducts Biktarvy1,570,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductHIVProducts Complera Eviplera75,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductHIVProducts Descovy437,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductHIVProducts Genvoya958,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductHIVProducts Odefsey435,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductHIVProducts Stribild71,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductHIVProducts Truvada768,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductOther Products Am Bisome110,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductOther Products Letairis96,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductOther Products Other58,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductOther Products Ranexa11,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductOther Products Vemlidy137,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductOther Products Viread39,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductOther Products Yescarta122,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductOther Products Zydelig24,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductProducts Other HIV10,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductProducts Revenue Share Symtuza125,000,000USDLegacy provider
    Q4 2019Quarterly · 2019-12-31ProductRoyalty Contract And Other83,000,000USDLegacy provider
    FY 2019Yearly · 2019-12-31ProductHCVProducts Ledipasvir Sofosbuvir643,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductHCVProducts Sofosbuvir Velpatasvir1,965,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductHCVProducts Vosevi257,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductHIVProducts Atripla600,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductHIVProducts Biktarvy4,738,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductHIVProducts Complera Eviplera406,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductHIVProducts Descovy1,500,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductHIVProducts Genvoya3,931,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductHIVProducts Odefsey1,655,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductHIVProducts Stribild369,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductHIVProducts Truvada2,813,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductOther Products Am Bisome407,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductOther Products Letairis618,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductOther Products Other285,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductOther Products Ranexa216,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductOther Products Vemlidy488,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductOther Products Viread243,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductOther Products Yescarta456,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductOther Products Zydelig103,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductProducts Other HIV47,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductProducts Revenue Share Symtuza379,000,000USD0000882095-20-000006
    FY 2019Yearly · 2019-12-31ProductRoyalty Contract And Other330,000,000USD0000882095-20-000006
    Q3 2019Quarterly · 2019-09-30ProductHCVProducts Ledipasvir Sofosbuvir124,000,000USD0000882095-19-000027
    Q3 2019Quarterly · 2019-09-30ProductHCVProducts Sofosbuvir Velpatasvir516,000,000USD0000882095-19-000027
    Q3 2019Quarterly · 2019-09-30ProductHCVProducts Vosevi63,000,000USD0000882095-19-000027
    Q3 2019Quarterly · 2019-09-30ProductHIVProducts Atripla149,000,000USD0000882095-19-000027
    Q3 2019Quarterly · 2019-09-30ProductHIVProducts Biktarvy1,259,000,000USD0000882095-19-000027

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.